Oculus Innovative Sciences (OCLS) to Collaborate with Amneal Pharmaceutical Alliance
Amneal Enterprises, an affiliation of independent pharmaceutical businesses, has announced the formation of a multi-year and multi-product collaboration with Oculus Innovative Sciences, Inc., an innovator and developer of tissue care products based upon the Microcyn® Technology platform. The agreement calls for AmDerma, an Amneal alliance member, to pay Oculus $500,000 as a non-refundable initial payment for an option to license Microcyn technology for the treatment of acne. It also calls for Quinnova Pharmaceuticals, another Amneal member, to pay $500,000 to Oculus, along with double-digit royalties, for the U.S. and Canadian rights to Microcyn-based dermatology atopic dermatitis hydrogel. In addition, under…